Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AXON
2051
Axon Enterprise
AXON
$51B
| $1.17M | ﹤0.01% |
2,091
+750
| +56% | +$314K |
|
2052
Indivior Pharmaceuticals
INDV
$4.35B
| $1.17M | ﹤0.01% |
28,545
+19,424
| +213% | +$705K |
|
2053
TriCo Bancshares
TCBK
$1.76B
| $1.17M | ﹤0.01% |
21,716
+4,584
| +27% | +$232K |
|
2054
PUT
BioNTech
BNTX
$29.3B
| $1.16M | ﹤0.01% |
12,500
| – | – |
|
2055
PUT
Zeta Global
ZETA
$7.3B
| $1.16M | ﹤0.01% |
+59,100
| New | +$1.1M |
|
2056
PUT
Bilibili
BILI
$7.14B
| $1.16M | ﹤0.01% |
67,900
-2,300
| -3% | -$46.6K |
|
2057
Sabesp
SBS
$16.2B
| $1.15M | ﹤0.01% |
199,798
+39,593
| +25% | +$240K |
|
2058
CALL
Best Buy
BBY
$18.1B
| $1.15M | ﹤0.01% |
+15,200
| New | +$1.01M |
|
2059
Expedia Group
EXPE
$38.6B
| $1.15M | ﹤0.01% |
4,506
-385,069
| -99% | -$91.5M |
|
2060
Bausch + Lomb
BLCO
$6.16B
| $1.15M | ﹤0.01% |
69,533
-63,729
| -48% | -$1.01M |
|
2061
CALL
AngloGold Ashanti
AU
$61.3B
| $1.15M | ﹤0.01% |
+14,200
| New | +$1.35M |
|
|
MBGL
2062
Mobility Global Inc
MBGL
$6.35B
| $1.14M | ﹤0.01% |
+51,891
| New | +$1.14M |
|
2063
PUT
Rigetti Computing
RGTI
$5.98B
| $1.14M | ﹤0.01% |
59,200
+45,800
| +342% | +$886K |
|
2064
Live Oak Bancshares
LOB
$1.9B
| $1.14M | ﹤0.01% |
27,935
+9,406
| +51% | +$352K |
|
2065
Public Storage
PSA
$60.2B
| $1.14M | ﹤0.01% |
3,584
+1,226
| +52% | +$375K |
|
2066
CALL
Opendoor
OPEN
$3.43B
| $1.14M | ﹤0.01% |
+246,600
| New | +$1.18M |
|
2067
PUT
Applied Digital
APLD
$7.74B
| $1.14M | ﹤0.01% |
30,500
-6,800
| -18% | -$262K |
|
2068
PUT
Gilead Sciences
GILD
$181B
| $1.14M | ﹤0.01% |
9,000
-3,200
| -26% | -$422K |
|
2069
Fulgent Genetics
FLGT
$548M
| $1.13M | ﹤0.01% |
+55,078
| New | +$934K |
|
2070
Rapid7
RPD
$799M
| $1.12M | ﹤0.01% |
+138,682
| New | +$919K |
|
2071
CALL
Quanterix
QTRX
$141M
| $1.12M | ﹤0.01% |
+260,000
| New | +$843K |
|
2072
Franklin Electric
FELE
$4.6B
| $1.12M | ﹤0.01% |
10,447
-46,798
| -82% | -$4.7M |
|
2073
Microchip Technology
MCHP
$41.3B
| $1.12M | ﹤0.01% |
12,276
-1,944,819
| -99% | -$173M |
|
|
AVLN
2074
Avalyn Pharma
AVLN
$1.7B
| $1.12M | ﹤0.01% |
+33,975
| New | +$980K |
|
2075
PUT
Pinterest
PINS
$13.3B
| $1.11M | ﹤0.01% |
+53,000
| New | +$1.06M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.